Home » Analysts See More FDA Concerns With Constipation Drugs Post-CRL
Analysts See More FDA Concerns With Constipation Drugs Post-CRL
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say. The agency may be cautious about a cardiovascular class-effect in mu-receptor antagonist candidates such as Relistor (methylnaltrexone bromide), Cantor Fitzgerald analyst Irina Rivkind writes.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May